网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
miR-122在肝细胞性肝癌中的表达及其与术后复发的关系
作者:周永平  华志元  丁文周  戴途 
单位:南京医科大学附属无锡第二医院 肝胆外科, 江苏 无锡 214000
关键词:微小RNA 肝细胞性肝癌 荧光定量PCR 预后 
分类号:R735.7
出版年·卷·期(页码):2018·46·第六期(621-625)
摘要:

目的:探讨肝细胞性肝癌组织中微小RNA-122(miR-122)的表达及其与患者术后复发的关系。方法:收集2013年6月至2014年6月在我院行肝癌根治手术的89例患者的临床资料、组织样本和随访信息,采用荧光定量PCR(qRT-PCR)检测癌组织和癌旁组织中miR-122的表达水平,分析miR-122的表达量与肝癌患者临床特征、术后复发的关系。结果:miR-122在癌组织的表达低于癌旁组织(P<0.05);肝癌组织中miR-122的表达量与病理组织分化程度、肿瘤直径、有无脉管癌栓、病人血清甲胎蛋白(AFP)值相关(P<0.05);单因素生存分析显示,miR-122低表达组患者术后无瘤生存时间明显缩短(P<0.05),肝癌组织中miR-122低表达是影响肝癌患者术后无瘤生存期的独立危险因素(P<0.01)。结论:miR-122在肝细胞性肝癌组织中低表达,与术后复发密切相关,可能作为判断肝细胞性肝癌病人预后的标志物。

Objective:To investigate the expression of microRNA -122(miR-122)in hepatocellular carcinoma and its relationship with postoperative recurrence. Methods:The clinical data, tissue samples and follow-up information of 89 patients who underwent the radical operation of liver cancer in our hospital from June 2013 to June 2014 were collected. The real time fluorescence quantitative PCR (qRT-PCR) was performed to detect the expression difference of miR-122 between carcinoma tissues and its adjacent normal tissue to analyze the relationship between the expression and clinical data and postoperative recurrence. Results:The expression of miR-122 in carcinoma tissues was markedly lower than that in its adjacent tissue (P<0.05). Moreover, the expression of miR-122 in hepatocellular carcinoma was significantly correlated with tumor differentiation, tumor diameter, vascular carcinoma, and AFP serum levels (P<0.05). The patients with lower expression of miR-122 in hepatocellular carcinoma had a statistically shorter tumor-free survival time (P<0.05).What's more, it's showed the lower expression of miR-122 in hepatocellular carcinoma was an independent risk factor for the tumor-free survival time of patients with hepatocellular carcinoma after operation(P<0.01). Conclusion:miR-122 is lowly expressed in hepatocellular carcinoma tissue and has a correlation with the patient's tumor-free survival. miR-122 may be a new prognostic biomarker.

参考文献:

[1] SIEGEL R,NAISHADHAM D,JEMAL A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.
[2] WILLATT J M,FRANCIS I R,NOVELLI P M,et al.Interventional therapies for hepatocellular carcinoma[J].Cancer Imaging,2012,12:79-88.
[3] SU X,XING J,WANG Z,et al.MicroRNAs and ceRNAs:RNA networks in pathogenesis of cancer[J].Chin Cancer Res,2013,25(2):235-239.
[4] XU Y,HUANG J,MA L,et al.MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways[J].Cancer Lett,2016,371(2):171-181.
[5] CHEN S L,LI F,CHAI H Y,et al.The expression and clinical significance of micro RNA-122 in different chronic liver diseases with HBV infection[J].Chin J Exp Clin Infect Dis(Electronic Version),2015,9(6):68-72.
[6] KARAKATSANIS A,PAPACONSTANTINOU I,GAZOULI M,et al.Expression of miRNAs,miR-21,miR-31,miR-122,miR-145,miR-146a,miR-200c,miR-221,miR-222 and miR-223 in pations with hepatocellulao caycinoma or intrahepatic cholangiocarcinoma and its prognostic significane[J].Mol Carcniog,2013,52(4):297-303.
[7] ZHUANG P,LI Z Y,WANG P C,et al.The functional characterization of the human liver-specific miR-122expression in hepatocullar carcinoma[J].China J Immun,2013,29(7):686-688.
[8] KISHIKAWA T,OTSUKA M,TAN P S,et al.Decreased miRl22 in hepatocellular carcinoma leads to chemoresistance with increased arginine[J].Oncotarget,2015,6(10):8339-8352.
[9] JIN J C,ZHANG X,JIN X L,et al.MicroRNA-122 regulation of the morphology and cytoarehitecture of hepatoma carcinoma cells[J].Mol Med Rep,2014,9(4):1376-1380.
[10] JIN J C,ZHANG X,JIN X L,et al.MicroRNA-122 regulation of the morphology and ytoarchitecture of hepatoma carcinoma cells[J].Mol Med Rep,2014,9(4):1376-1380.
[11] WAIDMANN O,BIHRER V,PLELI T,et al.Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virusinfection[J].J Viral Hepat,2012,19(2):58-65.
[12] KUTAY H,BAI S,DATTA J,et al.Downregulation of miR-122 in the rodent and human hepatocellular carcinomas[J].J Cell Biochem,2006,99(3):671-678.
[13] GRAMANTIERI L,FERRACIN M,FOMARI F,et al.Cyclin G1 is a target of miR-l 22.a microRNA frequently down-regulated in human hepatocellular carcinoma[J].Cancer Res,2007,67(13):6092-6099.
[14] NAKAO K,MIYAAKI H,ICHIKAWA T.Antitumor function of microRNA-122 against hepatocellular carcinoma[J].J Gastroenterol,2014,49(4):589-593.
[15] XU Y,BU X,DAI C,et al.High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients[J].Tumour Biol,2015,36(6):4773-4776.
[16] 杨颖卓,康鹏,高杰,等.肝特异性miR-122调控肝脏疾病的研究进展[J].临床肝胆病杂志,2014,30(5):473-477.
[17] 张迎建,李文超,杨红.microRNA+在预防医学中的研究进展[J].东南大学学报:医学版,2013,32(5):606-611.
[18] 韩力,刘琳.靶向VEGF/VEGFR路径治疗肝细胞癌的临床研究进展[J].东南大学学报:医学版,2017,36(2):240-244.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 729269 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541